deferasirox has been researched along with Carcinoma, Hepatocellular in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Akita, T; Jomen, W; Kohgo, Y; Ohtake, T; Osawa, Y; Suto, D; Yagi, H | 1 |
| Fujisawa, K; Hidaka, I; Ishikawa, T; Iwamoto, T; Maeda, M; Matsumoto, T; Saeki, I; Sakaida, I; Takami, T; Tani, K; Uchida, K; Yamamoto, N; Yamasaki, T | 1 |
| Brissot, P; Cannie, I; Gaboriau, F; Gouffier, L; Leray, AM; Lescoat, G; Loréal, O; Ropert, M; Troadec, MB | 1 |
| Aihara, Y; Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Namisaki, T; Noguchi, R; Shirai, Y; Tsujimoto, T; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
| Brissot, P; Chantrel-Groussard, K; Gaboriau, F; Havouis, R; Lescoat, G; Nick, H; Pasdeloup, N; Pierre, JL | 1 |
| Dassonville, A; Desplat, V; Gaboriau, F; Guillon, J; Jarry, C; Lescoat, G; Nascimento, S; Pires, VS; Rochette, J; Sonnet, P | 1 |
| Brissot, P; Chantrel-Groussard, K; Gaboriau, F; Lescoat, G; Nick, H; Pasdeloup, N | 1 |
1 trial(s) available for deferasirox and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Animals; Benzoates; Carcinoma, Hepatocellular; Deferasirox; Drug Screening Assays, Antitumor; Female; Hep G2 Cells; Humans; Iron Chelating Agents; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Middle Aged; Triazoles | 2016 |
6 other study(ies) available for deferasirox and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Topics: Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Line, Tumor; Deferasirox; Humans; Iron Chelating Agents; Liver Neoplasms; NF-kappa B; Sorafenib | 2022 |
Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
Topics: Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Deferasirox; Deferiprone; Dose-Response Relationship, Drug; Female; Ferritins; Hepatocytes; Humans; Iron; Iron Chelating Agents; Liver Neoplasms; Molecular Structure; Pyridones; Receptors, Transferrin; Triazoles | 2010 |
Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Topics: Administration, Oral; Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzoates; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Choline Deficiency; Deferasirox; Disease Progression; Drug Therapy, Combination; Fatty Liver; Hepatic Stellate Cells; Iron Chelating Agents; Liver Cirrhosis, Experimental; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Rats, Inbred F344; Time Factors; Transforming Growth Factor beta1; Triazoles | 2011 |
The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.
Topics: Acetyltransferases; Apoptosis; Benzoates; Biogenic Polyamines; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Deferasirox; DNA Replication; Ethylamines; Hepatocytes; Humans; Hydroxyquinolines; Iron Chelating Agents; Ornithine Decarboxylase; RNA, Messenger; Triazoles | 2006 |
Modulation of cell proliferation in rat liver cell cultures by new calix[4]arenes.
Topics: Animals; Benzoates; Calixarenes; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Deferasirox; Drug Screening Assays, Antitumor; Hydroxyl Radical; Iron Chelating Agents; Molecular Structure; Phenols; Rats; Solubility; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2006 |
Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.
Topics: Animals; Apoptosis; Base Sequence; Benzoates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Deferasirox; Deferiprone; DNA Primers; DNA Replication; Humans; Iron Chelating Agents; Liver Neoplasms; Liver Neoplasms, Experimental; Polyamines; Pyridones; Rats; Triazoles | 2007 |